易明医药(002826) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 338,753,077.45, representing a 36.21% increase compared to CNY 248,707,494.89 in the same period last year[22]. - The net profit attributable to shareholders of the listed company decreased by 22.84% to CNY 10,177,542.42 from CNY 13,189,425.35 year-on-year[22]. - The net profit after deducting non-recurring gains and losses increased by 13.67% to CNY 6,664,384.22 compared to CNY 5,863,045.75 in the previous year[22]. - The net cash flow from operating activities surged by 164.64% to CNY 21,337,384.56 from CNY 8,062,900.47 in the same period last year[22]. - Basic earnings per share decreased by 28.57% to CNY 0.05 from CNY 0.07 in the same period last year[22]. - Diluted earnings per share also decreased by 28.57% to CNY 0.05 from CNY 0.07 year-on-year[22]. - The weighted average return on net assets was 1.47%, down from 2.00% in the previous year[22]. - The company's gross profit margin decreased due to a higher increase in operating costs, which rose by 41.73% to ¥224,213,354.01 from ¥158,200,544.94 in the previous year[44]. - The company's net profit attributable to shareholders decreased by 22.84% year-on-year due to a 41.73% increase in operating costs and a 38.73% increase in selling expenses, both outpacing revenue growth[52]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 808,019,376.67, down 11.02% from CNY 908,087,426.76 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company decreased by 0.60% to CNY 683,012,629.91 from CNY 687,146,488.90 at the end of the previous year[22]. - The company's total liabilities decreased to CNY 125,006,746.76 from CNY 220,940,937.86, a reduction of about 43%[149][150]. - The company's current assets decreased to CNY 359,834,569.86 from CNY 450,252,514.19, reflecting a reduction of about 20%[147][148]. - Cash and cash equivalents dropped to CNY 142,867,586.31 from CNY 205,321,751.59, indicating a decrease of approximately 30%[147]. Revenue Sources and Growth - The company achieved a sales revenue of 338.75 million yuan, representing a year-on-year growth of 36.21%[35]. - The sales growth was primarily driven by third-party cooperative products such as Gua Lou Pi Injection, Sodium Nemephene Injection, and self-produced products like Miglitol Tablets and Domperidone Tablets[44]. - The cardiovascular segment generated ¥153,682,372.45, accounting for 45.37% of total revenue, with a year-on-year growth of 49.53%[48]. - Revenue from the cardiovascular sector increased by 49.53%, while revenue from the Gua Lou Pi injection (product sales) and (market promotion) rose by 94.31% and 45.80% respectively compared to the previous year[52]. - Revenue from the "other" sector grew by 54.28%, while costs in this sector increased by 65.49%, primarily due to the entry of Domperidone tablets into national centralized procurement[52]. Research and Development - Research and development expenses increased by 32.24% to ¥5,855,631.00, up from ¥4,428,099.20 in the previous year[46]. - The company is actively involved in the development of new products, including the raw material and injection project for L-arginine, aimed at treating patent ductus arteriosus (PDA)[35]. - The company has established a comprehensive R&D and production capability, with three R&D centers and two production centers, ensuring a strong competitive edge in product development[41]. Environmental Responsibility - The company is committed to environmental protection and has implemented measures to achieve energy conservation and emission reduction[37]. - The company has a daily wastewater treatment capacity of 450 tons, with an inflow COD concentration of approximately 2500 mg/L and an outflow COD concentration of 100 mg/L, significantly below the standard of 300 mg/L[84]. - The company has obtained a national pollutant discharge permit, with the permit number 91510000620854656KP001, which can be verified on the national pollutant discharge permit management information platform[86]. - The company has implemented a self-monitoring plan for pollutants, with wastewater monitored quarterly and air emissions monitored biannually[86]. Shareholder and Investor Relations - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company emphasizes a long-term stable profit distribution policy, prioritizing cash dividends to return value to shareholders[89]. - The company has maintained a focus on social responsibility, ensuring the protection of shareholder rights and enhancing investor relations through effective communication[88]. - The company completed the repurchase and cancellation of 490,125 restricted stock units due to not meeting performance targets for the previous year[81]. Miscellaneous - The company has not faced any administrative penalties for environmental issues during the reporting period, indicating compliance with environmental regulations[83]. - The financial report for the first half of 2021 was not audited[145]. - The company has not engaged in any significant related party transactions during the reporting period[104]. - The company has not encountered any major litigation or arbitration matters during the reporting period[102].